《異動股》科笛(02487.HK)急吐18% 來凱(02105.HK)續漲35%
恆指現報16,596,反覆回升85點或0.5%,總成交額931億元。此外,國指反覆升0.9%報5,731。
然而,醫藥股個別發展。科笛-B(02487.HK)終止連日升勢,最低見8.31元,現報8.37,瀉18%。該公司昨天公布,截至去年12月底止年度,集團已商業化產品之收入按年急增11倍至約1.38億元人民幣。單計去年末季,已商業化產品收入按年急增10.5倍至約7,280萬元人民幣。
綠竹生物-B(02480.HK)挫14%報21.4元。百濟神州(06160.HK)終止三連升,股價失守百天線(104元),曾低見97.5元,現報98.1元,回吐7.5%。直明昂科-B(01541.HK)挫7.7%報19.48元,股價失守20天線。信達生物(01801.HK)跌5.2%報40.15元。科倫博泰生物-B(006990.HK)由高位連跌第三天兼失守10天線,現報103.8元,續跌逾4%。
然而,來凱醫藥(02105.HK)自主研發的減肥新藥LAE 102臨床試驗申請獲受理,股價第三天受捧,股價繼昨天飆逾四成後,今天反覆高見8.75元,現報7.8元,續漲35%。
聖諾醫藥-B(02257.HK)終止連日創上市新低頹勢,最高見15.48元,現報13.86元,反彈8.6%。
藍籌藥明康德(02359.HK)反覆續升2.5%報49.9元;國藥(01099.HK)反覆回升3%報22.6元,股價重越250天線(22.4元)。騰盛博藥-B(02137.HK)止跌反彈2.4%報1.7元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.